107.08 +0.01 (0.01%)
After hours: 4:26PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||106.72 - 108.57|
|52 Week Range||86.25 - 119.05|
|PE Ratio (TTM)||42.20|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||114.83|
Charles River Laboratories International, Inc. recently announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, Feb. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tile ...
Stock Monitor: Fluidigm Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Charles River Laboratories International, ...
Moody's Investors Service ("Moody's") affirmed Charles Rivers Laboratories International Inc.'s ("Charles River") Ba2 Corporate Family Rating and Ba2-PD Probability of Default Rating, ...
Charles River Laboratories, one of the state’s largest life sciences companies, said it will acquire a Michigan-based contract research firm for $800 million. Wilmington-based Charles River Labs (CRL) said Tuesday that it would pay $800 million in cash for MPI Research, a privately held firm headquartered in Mattawan, Michigan. It marks Charles River’s second deal for a contract research organization, or CRO, so far this year.
On a per-share basis, the Wilmington, Massachusetts-based company said it had a loss of 63 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, were $1.40 per share. ...
Charles River Laboratories International, Inc. today reported its results for the fourth-quarter and full-year 2017 and provided guidance for 2018. For the quarter, revenue from continuing operations was $478.5 million, an increase of 2.5% from $466.8 million in the fourth quarter of 2016.
Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing adjustments.
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Charles River Laboratories International, Inc. today announced a new agreement which grants Charles River commercial access to AstraZeneca’s high-throughput screening and compound management infrastructure.
Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13th, before the market opens.
VANCOUVER , Jan. 17, 2018 /CNW/ - Trading resumes in: Company: Carl Data Solutions Inc. CSE Symbol: CRL, CRL.WT, CRL.RT Resumption (ET): 11:30 AM IIROC can make a decision to impose a temporary suspension ...
TORONTO , Jan. 17, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Carl Data Solutions Inc. CSE Symbol: CRL CRL.WT CRL.RT Reason: Pending News Halt Time (ET): 9:03 AM IIROC can make ...
Charles River Laboratories International, Inc. today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors. Mr. Mangeolle’s extensive experience leading global life science and bioscience companies, with a specific focus on high-end instrumentation, will provide Charles River with a unique combination of expertise.
Charles River Laboratories International, Inc. today announced that it has acquired KWS BioTest, a leading contract research organization specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases.
Charles River Laboratories International, Inc. announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9th, at 11:30 a.m.
Stock Monitor: iKang Healthcare Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free earnings report on Charles River Laboratories International, ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Charles River Laboratories International, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)
Charles River Labs International shows rising price performance, earning an upgrade to its IBD Relative Strength Rating